MMPs in ovarian cancer as therapeutic targets

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 7, 2012, Pages 764-772

  Karam, Amer ^a   Dorigo, Oliver ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Batimastat; Clinical trial; Intraperitoneal; Matrix metalloproteinase (MMP); Metastatic; Ovarian cancer; Peptomimetic; Prinomastat; Serum marker; Tanomastat; Tissue inhibitor of metalloproteinases (TIMP)

Indexed keywords

BATIMASTAT; CARBOPLATIN; CD147 ANTIGEN; COLLAGENASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GELATINASE A; GELATINASE B; GEMCITABINE; INTERSTITIAL COLLAGENASE; LYSOPHOSPHATIDIC ACID; MACROPHAGE ELASTASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PRINOMASTAT; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; REBIMASTAT; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; STROMELYSIN 3; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN;

ARTHRALGIA; CANCER PATIENT; CLEAR CELL CARCINOMA; CYSTADENOMA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DROWSINESS; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC TRANSCRIPTION; HEADACHE AND FACIAL PAIN; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MUSCULOSKELETAL DISEASE; MYALGIA; NEOPLASM; NONHUMAN; NOSE CONGESTION; OVARY CANCER; OVARY CARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RNA TRANSLATION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84866373884     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012802650174     Document Type: Review

References (87)

1. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin., 61 (2), 69-90.
2. Cai, K. Q.; Yang, W. L.; Capo-Chichi, C. D.; Vanderveer, L.; Wu, H.; Godwin, A. K.; Xu, X. X. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Mol. Carcinog., 2007, 46 (2), 130-143.
3. Ray, J. M.; Stetler-Stevenson, W. G. Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J., 1995, 14 (5), 908-917
4. Kleiner, D. E.; Stetler-Stevenson, W. G. Matrix metalloproteinases and metastasis. Cancer Chemother. Pharmacol., 1999, 43 Suppl, S42-S51.
5. Wang, F. Q.; So, J.; Reierstad, S.; Fishman, D. A. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int. J. Cancer, 2005, 114 (1), 19-31.
6. Wang, F. Q.; So, J.; Reierstad, S.; Fishman, D. A. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int. J. Cancer, 2006, 118 (4), 879-888.
7. Adley, B. P.; Gleason, K. J.; Yang, X. J.; Stack, M. S. Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma. Gynecol. Oncol., 2009, 112 (2), 319-324.
8. Zucker, S.; Hymowitz, M.; Conner, C.; Zarrabi, H. M.; Hurewitz, A. N.; Matrisian, L.; Boyd, D.; Nicolson, G.; Montana, S. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Annal. New York Acad. Sci., 1999, 878, 212-227.
9. Sutinen, M.; Kainulainen, T.; Hurskainen, T.; Vesterlund, E.; Alexander, J. P.; Overall, C. M.; Sorsa, T.; Salo, T. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. Br. J. Cancer, 1998, 77 (12), 2239-2245.
10. Murray, G. I.; Duncan, M. E.; Arbuckle, E.; Melvin, W. T.; Fothergill, J. E. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut, 1998, 43 (6), 791-797
11. Duncan, M. E.; Murray, G. I.; O'Neil, P.; Melvin, W. T.; Fothergill, J. E. Expression of matrix metalloproteinases in colorectal cancer. Biochemical Society transactions, 1996, 24 (2), 329S.
12. Kamel, H.; Abdelazim, I.; Habib, S. M.; El Shourbagy, M. A.; Ahmed, N. S. Immunoexpression of matrix metalloproteinase-2 (MMP-2) in malignant ovarian epithelial tumours. J. Obstet. Gynaecol. Can., 32 (6), 580-586.
13. Brun, J. L.; Cortez, A.; Commo, F.; Uzan, S.; Rouzier, R.; Darai, E. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int. J. Oncol., 2008, 33 (6), 1239-1246.
14. Perigny, M.; Bairati, I.; Harvey, I.; Beauchemin, M.; Harel, F.; Plante, M.; Tetu, B. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am. J. Clin. Pathol., 2008, 129 (2), 226-231.
15. Kamat, A. A.; Fletcher, M.; Gruman, L. M.; Mueller, P.; Lopez, A.; Landen, C. N., Jr.; Han, L.; Gershenson, D. M.; Sood, A. K. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin. Cancer Res., 2006, 12 (6), 1707-1714.
16. Sillanpaa, S.; Anttila, M.; Suhonen, K.; Hamalainen, K.; Turpeenniemi-Hujanen, T.; Puistola, U.; Tammi, M.; Sironen, R.; Saarikoski, S.; Kosma, V. M. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour. Biol., 2007, 28 (5), 280-289.
17. Sillanpaa, S.; Anttila, M.; Voutilainen, K.; Ropponen, K.; Turpeenniemi-Hujanen, T.; Puistola, U.; Tammi, R.; Tammi, M.; Sironen, R.; Saarikoski, S.; Kosma, V. M. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol. Oncol., 2007, 104 (2), 296-303.
18. Sillanpaa, S. M.; Anttila, M. A.; Voutilainen, K. A.; Ropponen, K. M.; Sironen, R. K.; Saarikoski, S. V.; Kosma, V. M. Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression. Int. J. Cancer, 2006, 119 (8), 1792-1799.
19. Kim, T. J.; Rho, S. B.; Choi, Y. L.; Choi, C. H.; Lee, J. W.; Bae, D. S.; Ahn, G.; Lee, J. H.; Kim, B. G. High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis. Hum. Pathol., 2006, 37 (7), 906-13.
20. Zohny, S. F.; Fayed, S. T. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med. Oncol., 27 (4), 1246-1253.
21. Acar, A.; Onan, A.; Coskun, U.; Uner, A.; Bagriacik, U.; Atalay, F.; Unsal, D. K.; Guner, H. Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer. Med. Oncol., 2008, 25 (3), 279-283.
22. Maatta, M.; Talvensaari-Mattila, A.; Turpeenniemi-Hujanen, T.; Santala, M. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Anticancer Res., 2007, 27 (4C), 2753-2758.
23. Li, Y.; Jia, J. H.; Kang, S.; Zhang, X. J.; Zhao, J.; Wang, N.; Zhou, R. M.; Sun, D. L.; Duan, Y. N.; Wang, D. J. The functional polymorphisms on promoter region of matrix metalloproteinase-12, -13 genes may alter the risk of epithelial ovarian carcinoma in Chinese. Int. J. Gynecol. Cancer, 2009, 19 (1), 129-133.
24. Six, L.; Grimm, C.; Leodolter, S.; Tempfer, C.; Zeillinger, R.; Sliutz, G.; Speiser, P.; Reinthaller, A.; Hefler, L. A. A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer. Gynecol. Oncol., 2006, 100 (3), 506-510.
25. Jin, H.; Yu, Y.; Zhang, T.; Zhou, X.; Zhou, J.; Jia, L.; Wu, Y.; Zhou, B. P.; Feng, Y. Snail is critical for tumor growth and metastasis of ovarian carcinoma. Int J Cancer, 126 (9), 2102-2111.
26. Satpathy, M.; Shao, M.; Emerson, R.; Donner, D. B.; Matei, D. Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity. J. Biol. Chem., 2009, 284 (23), 15390-15399.
27. Cowden Dahl, K. D.; Symowicz, J.; Ning, Y.; Gutierrez, E.; Fishman, D. A.; Adley, B. P.; Stack, M. S.; Hudson, L. G. Matrix metalloproteinase 9 is a mediator of epidermal growth factordependent e-cadherin loss in ovarian carcinoma cells. Cancer Res., 2008, 68 (12), 4606-4613.
28. Do, T. V.; Kubba, L. A.; Du, H.; Sturgis, C. D.; Woodruff, T. K. Transforming growth factor-beta1, transforming growth factorbeta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol. Cancer Res., 2008, 6 (5), 695-705.
29. Belotti, D.; Calcagno, C.; Garofalo, A.; Caronia, D.; Riccardi, E.; Giavazzi, R.; Taraboletti, G. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol. Cancer Res., 2008, 6 (4), 525-534.
30. Kenny, H. A.; Lengyel, E. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle, 2009, 8 (5), 683-688.
31. Kenny, H. A.; Kaur, S.; Coussens, L. M.; Lengyel, E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J. Clin. Invest., 2008, 118 (4), 1367-1379.
32. Said, N.; Socha, M. J.; Olearczyk, J. J.; Elmarakby, A. A.; Imig, J. D.; Motamed, K. Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res, 2007, 5 (10), 1015-1030.
33. Do, T. V.; Symowicz, J. C.; Berman, D. M.; Liotta, L. A.; Petricoin, E. F., 3rd; Stack, M. S.; Fishman, D. A. Lysophosphatidic acid downregulates stress fibers and up-regulates pro-matrix metalloproteinase- 2 activation in ovarian cancer cells. Mol. Cancer Res., 2007, 5 (2), 121-131.
34. Barbolina, M. V.; Adley, B. P.; Ariztia, E. V.; Liu, Y.; Stack, M. S. Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collageninduced EGR1 expression. J. Biol. Chem., 2007, 282 (7), 4924-4931.
35. Sood, A. K.; Bhatty, R.; Kamat, A. A.; Landen, C. N.; Han, L.; Thaker, P. H.; Li, Y.; Gershenson, D. M.; Lutgendorf, S.; Cole, S. W. Stress hormone-mediated invasion of ovarian cancer cells. Clin. Cancer Res., 2006, 12 (2), 369-375.
36. Wu, M.; Xu, G.; Xi, L.; Wei, J.; Song, A.; Han, Z.; Zhou, J.; Wang, S.; Zhu, T.; Zhang, A.; Lu, Y.; Ma, D. Down-regulation of MT1- MMP expression suppresses tumor cell invasion in metastatic human SW626 ovarian cancer cells. Oncol. Rep., 2006, 15 (2), 501-505.
37. Leroy-Dudal, J.; Demeilliers, C.; Gallet, O.; Pauthe, E.; Dutoit, S.; Agniel, R.; Gauduchon, P.; Carreiras, F. Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2. Int. J. Cancer, 2005, 114 (4), 531-543.
38. Hoskins, E.; Rodriguez-Canales, J.; Hewitt, S. M.; Elmasri, W.; Han, J.; Han, S.; Davidson, B.; Kohn, E. C. Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells. Gynecol. Oncol., 122 (3), 656-662.
39. Wang, F. Q.; Fisher, J.; Fishman, D. A. MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol. Oncol., 120 (2), 247-255.
40. Karam, A. K.; Santiskulvong, C.; Fekete, M.; Zabih, S.; Eng, C.; Dorigo, O. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken), 67 (8), 535-544.
41. Gomis-Ruth, F. X.; Maskos, K.; Betz, M.; Bergner, A.; Huber, R.; Suzuki, K.; Yoshida, N.; Nagase, H.; Brew, K.; Bourenkov, G. P.; Bartunik, H.; Bode, W. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature, 1997, 389 (6646), 77-81
42. Grams, F.; Crimmin, M.; Hinnes, L.; Huxley, P.; Pieper, M.; Tschesche, H.; Bode, W. Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry, 1995, 34 (43), 14012-14020.
43. Golub, L. M.; Lee, H. M.; Lehrer, G.; Nemiroff, A.; McNamara, T. F.; Kaplan, R.; Ramamurthy, N. S. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J. Periodontal Res., 1983, 18 (5), 516-526.
44. Golub, L. M.; Lee, H. M.; Ryan, M. E.; Giannobile, W. V.; Payne, J.; Sorsa, T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv. Dental Res., 1998, 12 (2), 12-26.
45. Hidalgo, M.; Eckhardt, S. G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Nat. Cancer Inst., 2001, 93 (3), 178-193.
46. Brown, P. D. Clinical studies with matrix metalloproteinase inhibitors. APMIS: Acta Pathologica, Microbiologica, et Immunol. Scand., 1999, 107 (1), 174-180.
47. Wojtowicz-Praga, S.; Low, J.; Marshall, J.; Ness, E.; Dickson, R.; Barter, J.; Sale, M.; McCann, P.; Moore, J.; Cole, A.; Hawkins, M. J. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Investigat. New Drugs, 1996, 14 (2), 193-202.
48. Macaulay, V. M.; O'Byrne, K. J.; Saunders, M. P.; Braybrooke, J. P.; Long, L.; Gleeson, F.; Mason, C. S.; Harris, A. L.; Brown, P.; Talbot, D. C. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clinical Cancer Research: An Official J. American Assoc. Cancer Res., 1999, 5 (3), 513-520.
49. Beattie, G. J.; Smyth, J. F. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clinical Cancer Research: An official Journal American Assoc. Cancer Res., 1998, 4 (8), 1899-1902.
50. Wojtowicz-Praga, S.; Torri, J.; Johnson, M.; Steen, V.; Marshall, J.; Ness, E.; Dickson, R.; Sale, M.; Rasmussen, H. S.; Chiodo, T. A.; Hawkins, M. J. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol.: Official J. Am. Soc. Clin. Oncol., 1998, 16 (6), 2150-2156.
51. Nemunaitis, J.; Poole, C.; Primrose, J.; Rosemurgy, A.; Malfetano, J.; Brown, P.; Berrington, A.; Cornish, A.; Lynch, K.; Rasmussen, H.; Kerr, D.; Cox, D.; Millar, A. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clinical Cancer Res.: An official J. American Assoc. Cancer Res., 1998, 4 (5), 1101-1109.
52. Steward, W. P.; Thomas, A. L. Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Exp. Opin. Investigat. Drugs, 2000, 9 (12), 2913-2922.
53. Quirt, I.; Bodurth, A.; Lohmann, R.; Rusthoven, J.; Belanger, K.; Young, V.; Wainman, N.; Stewar, W.; Eisenhauer, E. Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Investigat. New Drugs, 2002, 20 (4), 431-437.
54. Bramhall, S. R.; Rosemurgy, A.; Brown, P. D.; Bowry, C.; Buckels, J. A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol.: Official J. Am. Soc. Clin. Oncol., 2001, 19 (15), 3447-3455.
55. Vincenti, M. P.; Brinckerhoff, C. E. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res., 2002, 4 (3), 157-164
56. Lombard, M. A.; Wallace, T. L.; Kubicek, M. F.; Petzold, G. L.; Mitchell, M. A.; Hendges, S. K.; Wilks, J. W. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res., 1998, 58 (17), 4001-4007.
57. Rizvi, N. A.; Humphrey, J. S.; Ness, E. A.; Johnson, M. D.; Gupta, E.; Williams, K.; Daly, D. J.; Sonnichsen, D.; Conway, D.; Marshall, J.; Hurwitz, H. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin. Cancer Res.: An Official J. Am. Assoc. Cancer Res., 2004, 10 (6), 1963-1970.
58. Douillard, J. Y.; Peschel, C.; Shepherd, F.; Paz-Ares, L.; Arnold, A.; Davis, M.; Tonato, M.; Smylie, M.; Tu, D.; Voi, M.; Humphrey, J.; Ottaway, J.; Young, K.; Vreckem, A. V.; Seymour, L. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer, 2004, 46 (3), 361-368.
59. Erlichman, C.; Adjei, A. A.; Alberts, S. R.; Sloan, J. A.; Goldberg, R. M.; Pitot, H. C.; Rubin, J.; Atherton, P. J.; Klee, G. G.; Humphrey, R. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Annals of Oncology: Official J. Europ. Soc. Med. Oncol. / ESMO, 2001, 12 (3), 389-395
60. Rowinsky, E. K.; Humphrey, R.; Hammond, L. A.; Aylesworth, C.; Smetzer, L.; Hidalgo, M.; Morrow, M.; Smith, L.; Garner, A.; Sorensen, J. M.; Von Hoff, D. D.; Eckhardt, S. G. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J. Clin. Oncol.: Official J. Am. Soc. Clin. Oncol., 2000, 18 (1), 178-186.
61. Hirte, H.; Stewart, D.; Goel, R.; Chouinard, E.; Huan, S.; Stafford, S.; Waterfield, B.; Matthews, S.; Lathia, C.; Schwartz, B.; Agarwal, V.; Humphrey, R.; Seymour, A. L. An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin. Investigat. New Drugs, 2005, 23 (5), 437-443
62. Goel, R.; Chouinard, E.; Stewart, D. J.; Huan, S.; Hirte, H.; Stafford, S.; Waterfield, B.; Roach, J.; Lathia, C.; Agarwal, V.; Humphrey, R.; Walsh, W.; Matthews, S.; Seymour, L. An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5- fluorouracil/leucovorin. Investigat. New Drugs, 2005, 23 (1), 63-71.
63. Molina, J. R.; Reid, J. M.; Erlichman, C.; Sloan, J. A.; Furth, A.; Safgren, S. L.; Lathia, C. D.; Alberts, S. R. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anti-cancer Drugs, 2005, 16 (9), 997-1002.
64. Hande, K. R.; Collier, M.; Paradiso, L.; Stuart-Smith, J.; Dixon, M.; Clendeninn, N.; Yeun, G.; Alberti, D.; Binger, K.; Wilding, G. Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clinical Cancer Research: An Official J. Am. Assoc. Cancer Res., 2004, 10 (3), 909-915.
65. Shalinsky, D. R.; Brekken, J.; Zou, H.; Kolis, S.; Wood, A.; Webber, S.; Appelt, K. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Investigat. New Drugs, 1998, 16 (4), 303-313.
66. Heath, E. I.; Burtness, B. A.; Kleinberg, L.; Salem, R. R.; Yang, S. C.; Heitmiller, R. F.; Canto, M. I.; Knisely, J. P.; Topazian, M.; Montgomery, E.; Tsottles, N.; Pithavala, Y.; Rohmiller, B.; Collier, M.; Forastiere, A. A. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Investigat. New Drugs, 2006, 24 (2), 135-140.
67. Behrendt, C. E.; Ruiz, R. B. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thrombosis Haemostasis, 2003, 90 (4), 734-737.
68. Tamura, Y.; Watanabe, F.; Nakatani, T.; Yasui, K.; Fuji, M.; Komurasaki, T.; Tsuzuki, H.; Maekawa, R.; Yoshioka, T.; Kawada, K.; Sugita, K.; Ohtani, M. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): Nsulfonylamino acid derivatives. J. Med. Chem., 1998, 41 (4), 640-649.
69. Mant, T. G.; Bradford, D.; Amin, D. M.; Pisupati, J.; Kambayashi, Y.; Yano, Y.; Tanaka, K.; Yamada-Sawada, T. Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S- 3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers. Br. J. Clin. Pharmacol., 2007, 63 (5), 512-526
70. Van Marle, S.; van Vliet, A.; Sollie, F.; Kambayashi, Y.; Yamada-Sawada, T. Safety, tolerability and pharmacokinetics of oral S- 3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Internat. J. Clin. Pharmacol. Therapeut., 2005, 43 (6), 282-293.
71. Chiappori, A. A.; Eckhardt, S. G.; Bukowski, R.; Sullivan, D. M.; Ikeda, M.; Yano, Y.; Yamada-Sawada, T.; Kambayashi, Y.; Tanaka, K.; Javle, M. M.; Mekhail, T.; O'Bryant C. L.; Creaven, P. J. A phase I pharmacokinetic and pharmacodynamic study of s- 3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin. Cancer Res.: An Official J. Am. Assoc. Cancer Res., 2007, 13 (7), 2091-2099.
72. Heath, E. I.; Grochow, L. B. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs, 2000, 59 (5), 1043-1055
73. Zhang, X.; Gonnella, N. C.; Koehn, J.; Pathak, N.; Ganu, V.; Melton, R.; Parker, D.; Hu, S. I.; Nam, K. Y. Solution structure of the catalytic domain of human collagenase-3 (MMP- 13) complexed to a potent non-peptidic sulfonamide inhibitor: binding comparison with stromelysin-1 and collagenase-1. J. Mol. Biol., 2000, 301 (2), 513-524.
74. Levitt, N. C.; Eskens, F. A.; O'Byrne, K. J.; Propper, D. J.; Denis, L. J.; Owen, S. J.; Choi, L.; Foekens, J. A.; Wilner, S.; Wood, J. M.; Nakajima, M.; Talbot, D. C.; Steward, W. P.; Harris, A. L.; Verweij, J. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin. Cancer Res.: An Official J. Am. Assoc. Cancer Res., 2001, 7 (7), 1912-1922.
75. Lokeshwar, B. L. MMP inhibition in prostate cancer. Annals of the New York Academy of Sciences, 1999, 878, 271-289
76. Seftor, R. E.; Seftor, E. A.; De Larco, J. E.; Kleiner, D. E.; Leferson, J.; Stetler-Stevenson, W. G.; McNamara, T. F.; Golub, L. M.; Hendrix, M. J. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin. Exper. Metast., 1998, 16 (3), 217-225.
77. Cianfrocca, M.; Cooley, T. P.; Lee, J. Y.; Rudek, M. A.; Scadden, D. T.; Ratner, L.; Pluda, J. M.; Figg, W. D.; Krown, S. E.; Dezube, B. J. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J. Clin. Oncol.: Official J. Am. Soc. Clin. Oncol., 2002, 20 (1), 153-159.
78. Rudek, M. A.; Figg, W. D.; Dyer, V.; Dahut, W.; Turner, M. L.; Steinberg, S. M.; Liewehr, D. J.; Kohler, D. R.; Pluda, J. M.; Reed, E. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J. Clin. Oncol.: Official J. Am. Soc. Clin. Oncol., 2001, 19 (2), 584-592.
79. Chu, Q. S.; Forouzesh, B.; Syed, S.; Mita, M.; Schwartz, G.; Cooper, J.; Curtright, J.; Rowinsky, E. K. A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Investigat. New Drugs, 2007, 25 (4), 359-367.
80. Rudek, M. A.; New, P.; Mikkelsen, T.; Phuphanich, S.; Alavi, J. B.; Nabors, L. B.; Piantadosi, S.; Fisher, J. D.; Grossman, S. A. Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. J. Neuro-oncology, 2011.
81. Dezube, B. J.; Krown, S. E.; Lee, J. Y.; Bauer, K. S.; Aboulafia, D. M. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J. Clin. Oncol.: Official J. Am. Soc. Clin. Oncol., 2006, 24 (9), 1389-1394.
82. Davies, B.; Brown, P. D.; East, N.; Crimmin, M. J.; Balkwill, F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res., 1993, 53 (9), 2087-2091.
83. Parsons, S. L.; Watson, S. A.; Steele, R. J. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. European J. Surg. Oncol.: J. Europ. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol., 1997, 23 (6), 526-531.
84. Hirte, H.; Vergote, I. B.; Jeffrey, J. R.; Grimshaw, R. N.; Coppieters, S.; Schwartz, B.; Tu, D.; Sadura, A.; Brundage, M.; Seymour, L. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/ platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol. Oncol., 2006, 102 (2), 300-308.
85. Rasmussen, H. S.; McCann, P. P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol. Therapeut., 1997, 75 (1), 69-75.
86. Folgueras, A. R.; Pendas, A. M.; Sanchez, L. M.; Lopez-Otin, C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int. J. Develop. Biol., 2004, 48 (5/6), 411-424
87. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science, 2002, 295 (5564), 2387-2392.